PT - JOURNAL ARTICLE AU - Abhijit Duggal AU - Rachel Kast AU - Emily Van Ark AU - Lucas Bulgarelli AU - Matthew T. Siuba AU - Jeff Osborn AU - Diego Rey AU - Fernando G Zampieri AU - Alexandre B Cavalcanti AU - Israel S Maia AU - Denise M Paisani AU - Ligia N Laranjeira AU - Ary Serpa Neto AU - Rodrigo Octávio Deliberato TI - Identification of Acute Respiratory Distress Syndrome subphenotypes denovo using routine clinical data: a retrospective analysis of ARDS clinical trials AID - 10.1101/2021.07.08.21260102 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.08.21260102 4099 - http://medrxiv.org/content/early/2021/07/08/2021.07.08.21260102.short 4100 - http://medrxiv.org/content/early/2021/07/08/2021.07.08.21260102.full AB - Rationale The acute respiratory distress syndrome (ARDS) is a heterogenous condition, and identification of subphenotypes may help in better risk stratification.Objectives Identify ARDS subphenotypes using new simpler methodology and readily available clinical variables.Design Retrospective Cohort Study of ARDS trials.Setting Data from the U.S. ARDSNet trials and from the international ART trial.Participants 3763 patients from ARDSNet datasets and 1010 patients from the ART dataset.Primary and secondary outcome measures The primary outcome was 60-day or 28-day mortality, depending on what was reported in the original trial. K-means cluster analysis was performed to identify subgroups. For feature selection, sets. Sets of candidate variables were tested to assess their ability to produce different probabilities for mortality in each cluster. Clusters were compared to biomarker data, allowing identification of subphenotypes.Results Data from 4,773 patients was analyzed. Two subphenotypes (A and B) resulted in optimal separation in the final model, which included nine routinely collected clinical variables, namely: heart rate, mean arterial pressure, respiratory rate, bilirubin, bicarbonate, creatinine, PaO2, arterial pH, and FiO2. Participants in subphenotype B showed increased levels of pro-inflammatory markers, had consistently higher mortality, lower number of ventilator-free days at day 28, and longer duration of ventilation compared to patients in the subphenotype A.Conclusions Routinely available clinical data can successfully identify two distinct subphenotypes in adult ARDS patients. This work may facilitate implementation of precision therapy in ARDS clinical trials.Strengths and limitations of this studyLargest cohort of patients used to identify subphenotypes of ARDS patients.Subphenotypes were validated in the population of a large international ARDS randomized controlled trial.Subphenotypes were identified by using only routinely collected clinical data.Our use of data exclusively from randomized controlled trials does not prove generalizability to unselected ARDS populations.The clinical utility of the subphenotypes have to be validated in a prospective study.Competing Interest StatementAD, MS, FGZ, ABC, ISM, DMP, LNL declare no relevant financial conflicts of interest. RK, EVA, LB, JO, DR and ROD are employees of Endpoint Health, Inc. ASN reported receiving personal fees from Drager unrelated to the submitted work.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided informed consent in the original trials. This secondary analysis study was determined to be not human subject research and was thus exempt from IRB review by WIRB. Specifically de-identified samples and accompanying clinical information that were collected for another purpose will be used for this research. WIRB Work Order #1-1228617-1 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the ARDSnet studies (EDEN, FACTT, ARMA, ALVEOLI) is publicly available from the NHLBI ARDS Network (NHLBI ARDS Network) and data from the ART trial can be requested from study authors.